Market expansion Leverage nRichDX’s growing Revolution product line and recent CTC enrichment kits to target biotechnology labs and research institutions expanding liquid biopsy capabilities, including circulating tumor cell research and cfDNA/ctDNA analysis.

Strategic partnerships Highlight collaboration history with Agena and OraSure as proof points for joint development and access to broader customer bases; pursue additional OEM, academic, and contract research collaborations to accelerate adoption.

Workflow uplift Position the platform’s ability to improve workflow, increase test sensitivity, and reduce costs as a strong ROI driver for labs performing NGS, PCR, and microarray based liquid biopsy testing.

Competitive differentiation Emphasize 510K exemption, universal applicability across cfDNA cfRNA cfTNA, and high analyte yield to differentiate from competitors and address diagnostic accuracy concerns prevalent in liquid biopsy workflows.

Market readiness Target mid to large biotech labs and cancer research centers with growing liquid biopsy programs, offering training and support services to reduce adoption barriers and accelerate time to value.